Search for Clinical Trial Results

Hematologic Neoplasms - 25 Studies Found
Status | Study |
Recruiting |
Study Name: A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers Condition: Hematologic Neoplasms Date: 2015-02-13 Interventions:
|
Recruiting |
Study Name: Phase I Trial of BAY1251152 for Advanced Blood Cancers Condition: Hematologic Neoplasms Date: 2016-04-18 Interventions: Drug: BAY1251152 Weekly infusion of BAY1251152 in 21-day cycles. |
Completed |
Study Name: Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer. Condition: Hematologic Neoplasms Date: 2006-10-16 Interventions: Drug: CPX-351 (Cytarabine:Daunorubicin) Liposome Injection |
Completed |
Study Name: Biomarker Research for Personalized Medicine Condition: Hematologic Neoplasms Date: 2011-12-06 |
Completed |
Study Name: A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. Condition: Hematologic Neoplasms Date: 2008-02-18 Interventions: Drug: RO5045337 Multiple ascending doses |
Terminated |
Study Name: A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies Condition: Haematological Malignancies Date: 2010-03-02 Interventions:
|
Active, not recruiting |
Study Name: Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator Condition: Hematologic Neoplasms Date: 2013-02-26 Interventions: Drug: Panobinostat single agent panobinostat starting with last assigned dose and regimen which patient |
Active, not recruiting |
Study Name: Intra-bone Cord Blood Transplantation in Patients With Haematological Malignancies Condition:
|
Recruiting |
Study Name: Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation Condition: Haematological Malignancy Date: 2017-05-07 Interventions: Drug: Nivolumab Injection Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface rec |